Study summary

Blinatumomab raised 3-year survival for adults in remission from 68% to 85%

E1910 trial · 224 people randomized, phase 3 · Published July 2024, New England Journal of Medicine

85%alive at 3 years, vs 68% with chemotherapy alone

What was tested

Blinatumomab added to consolidation chemotherapy, against chemotherapy alone, for adults aged 30 to 70 with B-cell ALL in remission with no detectable residual leukemia.

What they found

3-year survival was 85% vs 68% (hazard ratio 0.41).
3-year relapse-free survival was 80% vs 64%.
Neurological and psychiatric side effects were more common with blinatumomab.

What it means

Made blinatumomab a standard part of adult treatment even when no leukemia can be detected.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.